Subacute sclerosing panencephalitis: A clinical appraisal

Sujit Abajirao Jagtap, M. D. Nair, Harsha J. Kambale
Departments of Neurology, and Imaging Sciences and Intervention Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India

Abstract

Introduction: Subacute sclerosing panencephalitis (SSPE) is a rare chronic, progressive encephalitis affecting primarily children and young adults, caused by a persistent infection of immune resistant measles virus. The aim of the present study is to describe the clinical profile and natural history of patients with SSPE. Methods: We collected data of patients with SSPE during 2004-2010 who fulfilled Dyken's criteria. We analyzed demographical, clinical, electrophysiological, and imaging features. Results: Study included 34 patients, 26 (76.5%) males with age of onset from 3 to 31 years. Twenty one patients were below 15 years of age formed childhood SSPE and 13 above 15 years of age constituted adult onset group. 85.3% had low-socioeconomic status. Eleven received measles vaccination and seven were unvaccinated. 59.9% patients had measles history. Most common presenting symptom was scholastic backwardness (52.5%) followed by seizures (23.5%). Three patients each had cortical blindness, macular degeneration, decreased visual acuity, and optic atrophy. Electroencephalographic (EEG) showed long interval periodic complexes and cerebrospinal fluid anti-measles antibody was positive in all. Magnetic resonance imaging was done in 70.5% with was abnormal in 52.5%. Mean incubation period of SSPE after measles was 9.6 years. The follow-up duration was 1-10 years, (average of 2 years). Only one patient died from available data of follow-up, 9 were stable and 10 deteriorated in the form of progression of staging. Conclusion: SSPE is common in low-socioeconomic status. The profile of adult onset did not differ from childhood onset SSPE, except for a longer interval between measles infection and presence of the ophthalmic symptom as presenting feature in adult onset group.

Key Words
Measles, myoclonus, subacute sclerosing panencephalitis

For correspondence:
Dr. Sujit Abajirao Jagtap, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum - 695 011, Kerala, India.
E-mail: sujitjagtap@gmail.com

Ann Indian Acad Neurol 2013;16:631-3

Introduction

Subacute sclerosing panencephalitis (SSPE) is a rare progressive demyelinating disease of the central nervous system associated with a chronic infection of brain tissue with measles virus, most commonly seen in children and young adults.[3] It is also called as Dawson's encephalitis after Dawson who first described it.[2] The term SSPE was coined by Greenfield. It is characterized by progressive intellectual deterioration, focal and/or generalized seizures, myoclonus, ataxia, and visual disturbances.[3] Most of the patients die within 1-3 years from onset of symptoms, although spontaneous improvement or stabilization can occur in a small proportion of patients.

SSPE generally follows the prevalence of measles in a population. The incidence rate in the USA in 1960 was 0.61 cases/million persons younger than 20 year. By 1980, the rate had fallen to 0.06 cases/million.[4] Incidence is still high in developing countries though variable, in India estimated incidence by Saha et al.[5] was 21/million population while an annual incidence of 1.5/million was reported in the Middle East.[6] Measles is primarily disease of childhood with age of onset before 2 years. After a latent period of 6-8 years, it is followed by onset of progressive neurological symptoms suggestive of SSPE. The measles vaccine has changed the epidemiology of measles dramatically from the erstwhile worldwide distribution to a rare disorder in developed countries. As a result of subclinical measles infection before the age of 1 year, occasionally, it can be seen in vaccinated children. There is no evidence to suggest that attenuated vaccine virus is responsible for sporadic cases of SSPE.[6,7] Individuals with acquired immunodeficiency syndrome (AIDS) or children whose mothers have AIDS might be at higher risk of a fulminant course and earlier onset of SSPE.[8]
Methods

We abstracted data of patients with SSPE during 2004-2010 who fulfilled Dyken’s criteria. The diagnosis of SSPE can be established, if the patient fulfills any three of the following five criteria: (1) Typical clinical presentation with progressive intellectual deterioration with signs of myoclonus; (2) characteristic electroencephalographic (EEG) pattern; (3) elevated cerebrospinal fluid (CSF) globulin levels; (4) elevated CSF measles antibody titer; and (5) brain biopsy suggestive of measles. We analyzed demographical, clinical, electrophysiological, and imaging features.

Results

There were 34 patients, 26 (76.5%) males and 8 (23.5%) females. Minimum age of onset was 3 years and maximum age was 31 years. Only two patients were below 5 years of age and 13 patients were above 15 years of age. 85.3% were from low-socioeconomic status. Out of 34 patients vaccination data was available in 18 patients of whom 11 were vaccinated and 7 were not vaccinated, remaining patients were unsure about vaccination status. 59.9% patients had history of measles while 41.1% did not. Most common presenting symptom was scholastic decline in which myoclonic seizures followed by seizures in 23.5% in which myoclonic seizures was most common presentation. Fundus examination was abnormal in 20.6%, in the form of macular involvement, optic atrophy, and retinal hemorrhages. Three patients had cortical blindness, three patients had macular degeneration, three patients had decreased visual acuity, and three had optic atrophy. The mean age of onset of measles was 3.3 years in childhood and 5.0 years in adult onset SSPE group. The mean age of onset of symptoms was 10.4 years in childhood onset (<15 years) while 19.3 years in adult onset. Mean incubation period of SSPE after measles was 9.6 years (childhood onset 5.9 and adult onset 14.9). The age of onset of SSPE and measles vaccination status were statistically insignificant.

Results

| Author | No. of cases | Study period | Mean age (years) | M:F | Age of onset >15-20 | History of measles % | Measles vaccination % | EEG % | CSF % | Follow-up duration |
|--------|--------------|--------------|-----------------|-----|--------------------|----------------------|----------------------|-------|-------|------------------|
| Lekhra et al.[9] | 39 | 1983-1993 | 11.5±3.5 | 2.9:1 | 6 | 41 | 41 | 97.4 | 79.4 | - |
| Saha et al.[1] | 82 | 1983-1987 | 10 | 2.4:1 | 3 | 70.7 | - | 100 | - | - |
| Bhat et al.[9] | 32 | 1984-1992 | 6.1 | 3:1 | 6 | 59.3 | 0 | 100 | 88.5 | 2 months to 5 years |
| Khare et al.[11] | 65 | 1982-1992 | - | 6:1 | - | 93.8 | 0 | 100 | - | - |
| Prashanth et al.[2] | 39 | 1995-2004 | 20-9:4.9 | 1.7:1 | 39 | 30 | - | - | 11.1±14.8 months |
| Prashanth et al.[2] | 268 | 1995-2004 | 10.5±3.6 | 3:1 | 0 | 27.9 | - | - | 12.9±23.8 months |
| Lakshmi et al.[4] | 33 | 1989-1992 | 10 | 2.3:1 | 4 | 42.4 | 3.3 | 100 | 90.9 | - |
| Manayani et al.[3] | 49 | 1996-1998 | 13 | 2.7:1 | 40 | 24 | 83 | 100 | - | - |
| Singh[3] | 39 | 1964-1994 | 11.2 | 12:1 | 7 | 15.7 | 0 | 90.5 | - | - |
| Khwaja et al.[17] | 36 | 1985-1989 | 6.2:1 | 8 | 51.3 | 0 | 94.4 | 36.4 | - | - |
| Shaikh and Rodrigues[18] | 32 | 1984-1989 | - | 2.5:1 | 1 | 91.1 | - | 95.0 | 90.5 | - |
| Mishra[9] | 114 | 1992-2001 | 9.3 | 3.2:1 | 10.3 | 3.5 | 77 | 100 | - | - |
| Sonia et al.[25] | 458 | 1996-2005 | 13.3 | 4.4:1 | 71 | - | - | - | 100 | - |
| Khadilkar et al.[21] | 32 | 1998-2003 | 13.4 | 3:1 | 4 | 62.5 | 35.5 | - | - | - |
| Present study | 34 | 2004-2010 | 13.4 | 3.2:1 | 13 | 59.9 | 61.2 | 100 | 100 | 2 years |

EEG=Electroencephalographic, CSF=Cerebrospinal fluid, M=Male, F=Female

Discussion

In India, SSPE is still common neurodegenerative disorder despite increase in measles vaccination. Population based studies are very few, however, many studies from all parts of country have been reported with nearly same features [Table 1]. Although measles infection is equally common in both sexes, higher incidence (male/female ratio 3:1) has been noted in boys, in childhood onset SSPE. This may be attributed to increased risk of being intensively exposed within the home for boys as compared to girls as per Aaby et al.[22] In adult onset SSPE, the gender distribution is reported to be equal, however, in our cohort, there was a preponderance of males (9 males and 2 females), similar to study by Prashant et al.[12]
The incidence is high among children from lower-socioeconomic levels, large family size, and rural area as measles virus is transmitted by respiratory secretions, predominantly through exposure to aerosols but also through direct contact with larger droplets.[23,24] Mean age of onset of SSPE is in early second decade in most of the studies while in study by Bhat et al. it was 6.1 year. There are very few adult onset SSPE cases in literature, largest series of 39 patient by Prashant et al.[25] followed by present study (13 patients) consisting 38.2% of cohort. The study by Sonia et al.[26] consisted of 71 adult patients but data of only four patients is available. The findings of that study are also comparable with study by Prashant et al. and present study. In the study by Prashant et al. mean age of onset of symptom in adult onset SSPE was 20.9 years similar to 19.3 years in our study. The clinical presentation of adult onset differs from childhood onset as, personality change and ophthalmic manifestations are common presenting features.[25,26] In the present series, six patients presented with either cognitive or behavioral changes, four had ophthalmic symptoms, and three had myoclonus at onset.

Follow-up data is very scarce with maximum follow-up being 5 years in study though some individual case reports have Long duration follow-up. The course of adult onset SSPE is generally postulated to have an aggressive course but Singer et al.[27] reported higher rate of spontaneous remission and favorable response to disease modifying agents in adult onset group. In present study, the average follow-up in adult onset group was 3.1 years compared to 1.5 years in childhood onset group, so it is not possible to comment on the length of patient survival. As compared to pre-immunization, there has been no significant change in the mean age of presentation in patients of SSPE. It has increased to 13 years from around 10 years.[12,19,20] The preponderance of male patients continues, though less prominent as well as its association with low-socioeconomic status. The presence of SSPE in vaccinated patients indicates either previous subclinical infection prior to measles vaccination or poor maintenance of cold chain.[12,19,20] SSPE is a devastating disorder that deserves elimination through the vaccination or poor maintenance of cold chain.

SSPE is common in low-socioeconomic status. The profile of adult onset did not differ from childhood onset SSPE, except for a longer interval between measles infection and presence of the ophthalmic symptom as presenting feature in adult onset group.

**References**

1. Agnarsdottir G. Subacute sclerosing panencephalitis. In: Waterson AP, editor. Recent Advances in Clinical Virology. New York: Churchill Livingstone; 1977. p. 21-49.
2. Dawson JR. Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol 1933;9:7-16.3.
3. Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin 1985;3:179-96.
4. Centers for Disease Control (CDC). Subacute sclerosing panencephalitis surveillance -United States. MMWR Morb Mortal Wkly Rep 1982;31:585-8.
5. Saha V, John TJ, Mukundan P, Gnanamuthu C, Prabhakar S, Arjundas G, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect 1990;104:151-6.
6. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007;36:1334-48.
7. Dullcs P, Ward BJ. Measles vaccines: A review of adverse events. Drug Saf 1998;19:435-54.
8. Koppel BS, Poon TP, Khandji A, Pavlakis SG, Pedley TA. Subacute sclerosing panencephalitis and acquired immunodeficiency syndrome: Role of electroencephalography and magnetic resonance imaging. J Neuroimaging 1996;6:122-5.
9. Lekhra OP, Thussu A, Sawhney IM, Prabhakar S, Chopra JS. Clinical profile of subacute sclerosing panencephalitis (SSPE). Neuro India 1996;44:10-5.
10. Bhat AR, Nair MD, Sarada C, Radhakrishnan K. Subacute sclerosing panencephalitis: Experience of a tertiary referral centre in Thiruvanthapuram, Kerala. Neurol India 1996;44:6-9.
11. Khare S, Kumari S, Sengal S. Sero-epidemiology of subacute sclerosing panencephalitis in Delhi. Indian J Med Res 1990;91:94-7.
12. Prashanth LK, Taly AB, Ravi V, Sinha S, Arunodaya GR. Adult onset subacute sclerosing panencephalitis: Clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry 2006;77:630-3.
13. Prashanth LK, Taly AB, Ravi V, Sinha S, Rao S. Long term survival in subacute sclerosing panencephalitis: An enigma. Brain Dev 2006;28:447-52.
14. Lakshmi V, Malathy Y, Rao RR. Serodiagnosis of subacute sclerosing panencephalitis by enzyme linked immunosorbent assay. Indian J Pediatr 1993;60:37-41.
15. Manayani DJ, Abraham M, Gnanamuthu C, Solomon T, Alexander M, Sridharan G. SSPE-The continuing challenge: A study based on serological evidence from a tertiary centre in India. Indian J Med Microbiol 2002;20:16-8.
16. Singhal BS, Wadia NH, Vibhakar BB, Dastur DK. Subacute sclerosing panencephalitis. I-Clinical aspects. Neurol India 1974;22:87-94.
17. Khwaja GA, Gupta M, Sharma DK. Subacute sclerosing panencephalitis. J Assoc Physicians India 1991;39:928-33.
18. Shaikh NJ, Rodrigues JJ. Serological studies on subacute sclerosing panencephalitis. Indian J Pediatr 1991;58:833-5.
19. Mishra B, Kakkar N, Ratho RK, Singhi P, Prabhakar S. Changing trend of SSPE over a period of ten years. Indian J Public Health 2005;49:235-7.
20. Sonia M, Lalit D, Shobha B, Sheffali G, Armandeep S, Veena K, et al. Subacute sclerosing panencephalitis in a tertiary care centre in post measles vaccination era. J Commun Dis 2009;41:161-7.
21. Khadilkar SV, Patil SG, Kulkarni KS. A study of SSPE: Early clinical features. J Pediatr Neurol 2004;2:73-7.
22. Aaby P, Bukh J, Lisse IM, Smits AJ. Risk factors in subacute sclerosing panencephalitis: Age- and sex-dependent host reactions or intensive exposure? Rev Infect Dis 1984;6:239-50.
23. Halsey NA, Modlin JF, Jabbour JT, Dubey L, Eddins DL, Ludwig DD. Risk factors in subacute sclerosing panencephalitis: A case-control study. Am J Epidemiol 1980;111:415-24.
24. Zilber N, Kahana E. Environmental risk factors for subacute sclerosing panencephalitis (SSPE). Acta Neurol Scand 1998;99:49-54.
25. Tan E, Namer IJ, Ciger A, Zileli T, Kucukali T. The prognosis of subacute sclerosing panencephalitis in adults. Report of 8 cases and review of the literature. Clin Neurol Neurosurg 1991;93:205-9.
26. Singer C, Lang AE, Suchowersky O. Adult-onset subacute sclerosing panencephalitis: Case reports and review of the literature. Mov Disord 1997;12:342-53.